Patient being treated for depression with difficulty waking up for which aripiprazole was prescribed
Conditions
Interventions
None listed
Sponsors
Kurume University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who have been diagnosed with major depressive disorder by DSM-V (Diagnostic and Statistical Manual of Disorders) and being treated with antidepressants. 2. Willingness and ability to follow the procedures of this study, including response to wearing the actigraph and consent to information collection. (In the case of minors, consent will be obtained from parents and guardians.)
Exclusion criteria
Exclusion criteria: 1. Patients witha history of serious psychosomatic disorders. 2. Patients with a history of suicidal ideation or attempts. 3. Patients taking aripiprazole with contraindications or precautions. 4. Pregnant women, patients who may become pregnant, patients who wish to become pregnant, and lactating patients. 5. Patients who are deemed incapable of consenting to research. 6. Patients who are otherwise classified as unfit by the attending physicians for the research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Aripiprazole is administered for 28 days, and actigraph and PSG are performed before and after administration. Actigraphic and PSG data will be investigated. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1,Japanese version of Karolinska. Sleepiness Scale:State of sleepiness 2,Visual Analog Scale: Difficulty falling asleep, awakening in the middle of the day, difficulty sleeping soundly, mood, evaluation of sleepiness 3,Epworth sleepiness Scale: Subfective sleep quality 4,the Japanese version of the Pittsburgh Sleep Quality Index: Subjective sleep quality severity | — |
Countries
Japan
Contacts
Public ContactHayato Ohshima
Kurume University School of Medicine Department of Neuropsychiatry
Outcome results
None listed